Skip to main content
SAMJIN PHARMACEUTICAL CO.,LTD logo

SAMJIN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 005500 ISIN · KR7005500004 KO Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2020-03-05 Capital/Financing Update
Country KR South Korea
Listing KO 005500

About SAMJIN PHARMACEUTICAL CO.,LTD

https://www.samjinpharm.co.kr/

Samjin Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes a wide range of over-the-counter (OTC) and prescription drugs, offered in various formulations such as oral, drop, and injectable forms. Notable products include the analgesic Gevorin, the antiplatelet agent Plavix, and the hypercholesterolemia treatment Newstatin-R. A central part of its strategy is a strong commitment to R&D, focusing on creating innovative new drugs to address diseases with high unmet medical needs. The company actively develops novel therapeutics for severe conditions, including cardiovascular, respiratory, and gastrointestinal diseases, with the goal of becoming a global pharmaceutical innovator.

Recent filings

Filing Released Lang Actions
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변경
Capital/Financing Update Classification · 95% confidence The document is a regulatory filing from Samjin Pharmaceutical regarding a correction to a previously disclosed 'Change in Sales or Profit/Loss Structure' (a common Korean regulatory disclosure requirement). It details specific financial adjustments (operating profit, net income, etc.) due to audit findings. Since this is a formal regulatory disclosure of financial data changes rather than a full annual report, an earnings release, or a simple announcement of a report, it falls under the 'Regulatory Filings' category as the most appropriate fallback for this type of specific financial correction filing.
2020-03-05 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Samjin Pharmaceutical. It details the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits). This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of upcoming meeting details and to request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2020-02-17 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Management Reports Classification · 95% confidence The document is a regulatory filing from Samjin Pharmaceutical regarding a change in revenue or profit structure (exceeding 15% for large corporations). It provides preliminary financial results (revenue, operating profit, net income) for the fiscal year compared to the previous year. This type of disclosure is a standard preliminary earnings announcement in the Korean market, which falls under the 'Earnings Release' category as it provides key financial highlights before the final audited report is published.
2020-02-03 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required by the Financial Services Commission in South Korea when an entity (in this case, the National Pension Service) crosses a 5% ownership threshold in a listed company (Samjin Pharmaceutical). This falls under the category of Major Shareholding Notification.
2020-01-06 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Samjin Pharmaceutical regarding a decision on cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the board resolution date. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2019-12-17 Korean
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Samjin Pharmaceutical Co., Ltd. for the 3rd quarter of the 52nd fiscal year (covering 2019-01-01 to 2019-09-30). It contains detailed financial statements, management analysis, and operational data, which fits the definition of an Interim/Quarterly Report (IR). 9M 2019
2019-11-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.